Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis - Multicentre study of 263 Caucasian patients
Rheumatology (United Kingdom), Volume 61, No. 1, Year 2022
Notification
URL copied to clipboard!
Description
Objective: To assess the efficacy and safety of abatacept (ABA) in monotherapy (ABAMONO) vs combined ABA [ABA plus MTX (ABAMTX) or ABA plus non-MTX conventional synthetic DMARDs (csDMARDs) (ABANON-MTX)] in RA patients with interstitial lung disease (ILD) (RA-ILD). Methods: This was a restrospective multicentre study of RA-ILD Caucasian patients treated with ABA. We analysed in the three groups (ABAMONO, ABAMTX, ABANON-MTX) the following outcome variables: (i) dyspnoea; (ii) forced vital capacity (FVC) and diffusion capacity of the lung for the carbon monoxide (DLCO); (iii) chest high-resolution CT (HRCT); (iv) DAS28-ESR; (v) CS-sparing effect; and (vi) ABA retention and side-effects. Differences between basal and final follow-up were evaluated. Multivariable linear regression was used to assess the differences between the three groups. Results: We studied 263 RA-ILD patients (mean ± s.d. age 64.6 ± 10 years) [ABAMONO (n = 111), ABAMTX (n = 46) and ABANON-MTX (n = 106)]. At baseline, ABAMONO patients were older (67 ± 10 years) and took higher prednisone dose [10 (interquartile range 5-15) mg/day]. At that time, there were no statistically significant differences in sex, seropositivity, ILD patterns, FVC and DLCO, or disease duration. Following treatment, in all groups, most patients experienced stabilization or improvement in FVC, DLCO, dyspnoea and chest HRCT as well as improvement in DAS28-ESR. A statistically significant difference between basal and final follow-up was only found in CS-sparing effect in the group on combined ABA (ABAMTX or ABANON-MTX). However, in the multivariable analysis, there were no differences in any outcome variables between the three groups. Conclusion: In Caucasian individuals with RA-ILD, ABA in monotherapy or combined with MTX or with other conventional-DMARDs seems to be equally effective and safe. However, a CS-sparing effect is only observed with combined ABA. © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
Authors & Co-Authors
Fernández-Díaz, Carlos
Spain, Santander
Universidad de Cantabria
Atienza-Mateo, Belén
Spain, Santander
Universidad de Cantabria
Castañeda, Santos
Spain, Madrid
Instituto de Investigación Sanitaria Hospital Universitario de la Princesa
Melero-González, Rafael Benito
Unknown Affiliation
Ortiz-Sanjuán, Francisco Miguel
Unknown Affiliation
Loricera, Javier
Spain, Santander
Universidad de Cantabria
Raya Álvarez, Enriqué G.
Unknown Affiliation
Bonilla-Hernán, Gema
Unknown Affiliation
Narváez, Javier A.
Unknown Affiliation
Maíz Alonso, Olga
Spain, Donostia-san Sebastian
Osakidetza, Donostia University Hospital
Ferraz-Amaro, Iván
Unknown Affiliation
González-Gay, Miguel Ángel
Spain, Santander
Universidad de Cantabria
Blanco-Alonso, Ricardo
Spain, Santander
Universidad de Cantabria
Statistics
Citations: 10
Authors: 13
Affiliations: 6
Identifiers
Doi:
10.1093/rheumatology/keab317
ISSN:
14620324
Research Areas
Environmental
Study Design
Cohort Study